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Abstract
Background:The pandemic following the rapid spread of the new SARS-CoV-2 virus has hit all continents and caused thousands
of deaths worldwide. Evidence has been published on epidemiological and clinical characteristics of population groups considered at
risk; however, information for the other population groups, especially for the child population, is needed. In this context, this protocol
describes a systematic review that will aim to identify the evidence on control and prevention of COVID-19 transmission
among children and adolescents, as well as to describe the epidemiological profile and clinical and immunological characteristics of
COVID-19 in this population.
Methods: This protocol will be developed in accordance with PRISMA-P. The searches will be conducted in PubMed, Web of
Science, ScienceDirect, EMBASE, and Scopus, seeking clinical trials. Observational studies and case reports with Children and
adolescents (19 years) infected with SARS-CoV-2 will be included whether they report information on the control of prevention and
COVID-19 transmission. Two independent researchers will perform the selection of articles, removal of duplication, and screening by
Rayyan QCRI application. Cochrane’s RoB 2.0, ROBINS-I, and CASP tools will be used to assess the risk of bias. Meta-analysis,
subgroup analyses, and/or descriptive analyses will be carried out based on the data conditions included.
Results: A high-quality synthesis of the available evidences on the epidemiological profile, the clinical and immunological
characteristics involved in children, and adolescents diagnosed with COVID-19, as well as the participation of this population in the
transmission dynamics of SARS-CoV-2 will be provided.
Conclusion: This systematic review has an important relevance in the current context because it has a great potential to help the
development of new control and prevention strategies in the pediatric population.
Record of systematic review: CRD42020179263.
Abbreviations: CASP = Critical Appraisal Skills Program, COVID-19 = Corona Virus Disease (2019), PRISMA = Preferred
Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA-P = Preferred Reporting Items for Systematic Reviews and
GCBSM and ACFN contributed equally to this work.
The authors report no conflicts of interest.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
a Department of Public Health, Postgraduate Program in Public Health, Federal University of Rio Grande do Norte, Natal/RN, Brazil, b Department of Administration
(Campus PM), Postgraduate Program in Management of Public Organizations, Federal University of Santa Maria, Santa Maria/RS, Brazil, cMulticampi School of Medical
Sciences of RN, Federal University of Rio Grande do Norte, Caicó/RN, Brazil, dMultiprofessional Residency Program of Interiorization Health Care, Federal University of
Pernambuco, Vitória de Santo Antão/PE, Brazil, e Department of Pharmacy, Faculty of Health Sciences, University of Brasilia (UnB), f Center for Health Sciences, Federal
University of Paraíba (UFPB), Paraiba, Brazil, g Federal Institute of Ceará — Aracati Campus, Brazil, h Research Center in Sports Sciences, Health and Human
Development, CIDESD, Vila Real, Portugal, i Faculty of Nursing, Catholic University of Murcia (UCAM), Murcia, Spain.
∗
Correspondence: Kesley Pablo Morais de Azevedo, Department of Public Health, University Campus Lagoa Nova, CEP 59078-970 Natal/RN, Brazil (e-mail:
kesley@ufrn.edu.br).
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
How to cite this article: Medeiros GC, Nunes AC, Azevedo KP, Segundo VH, Santos GM, Mata ÁN, Pimenta ID, Bezerra IN, Braga LP, Capucho HC, Piuvezam MR,
Filho VC, Leitão JC, Martínez DG, Piuvezam G. The Control and Prevention of Covid-19 Transmission In Children: A Protocol For Systematic Review And Meta-
Analysis. Medicine 2020;99:31(e21393).
Received: 22 June 2020 / Accepted: 23 June 2020
http://dx.doi.org/10.1097/MD.0000000000021393
Study Protocol Systematic Review Medicine®
OPEN
1
Meta-Analyses Protocols, RoB = Risk of bias, ROBINS-I = Risk of Bias in Non-Randomised Studies – of Interventions, SARS-CoV-2
= Severe Acute Respiratory Syndrome Coronavirus 2.
Keywords: children, adolescents, COVID-19, SARS-CoV-2 infection
1. Introduction
The contemporary pandemic declared by the World Health
Organization (WHO) after the rapid spread of the new Severe
Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2 virus)
has hit all continents and caused thousands of deaths worldwide.
WHO later named it a disease caused by coronavirus 2019 or
COVID-19.[1]
The observed and published data on the infection and
mortality rates of COVID-19 point to the existence of more
vulnerable groups, especially elderly individuals and patients
with chronic diseases. In this sense, many information has been
published on the epidemiological and clinical characteristics of
these population groups.[2] However, technical and scientific
information are needed for the other population groups,
especially for the infant population.
A recent systematic review study analyzed publications on
COVID-19 in the infant population and found a reduced
possibility of contagion (dissemination) in this group ranging
from 1% to 5%.[3] The explanatory hypothesis that stands out is
the insufficient rate of tests performed in children, mainly because
most of these individuals are asymptomatic, according to a study
by Bi et al (2020) that analyzed >2000 children with COVID-19
and >90% of them were asymptomatic or had very mild
symptoms.[4]
Another systematic review study (Castagnoli et al, 2020) that
approached the main clinical features and management of
pediatric cases of SARS-CoV-2 infection showed that most of the
evidence results from clinical studies and cases in China. The
summary of the evidence indicated that children mainly acquire
SARS-CoV-2 infection from their relatives, but seem to
experience a less severe form of the disease compared to adults,
presentingmild symptoms and in cases of good prognosis, there is
recovery within 1 to 2 weeks.[5] These findings are corroborated
by the study by Rasmissen and Thompson 2020; however, the
authors also highlight that there are gaps, especially with regard
to the effects of the disease in children with special health needs.[6]
Another research conducted with Spanish children also indicated
the need for additional information to trace the characteristics of
the disease in this population.[7]
In this context, considering that this infant population resides
with other individuals (parents, grandparents, or guardians) the
probability of becoming transmitters of COVID-19 to family
members becomes high, especially because they are asymptom-
atic. Thus, in order for new control and prevention strategies to
be idealized, understanding the dynamics of transmission and
control of the virus in this population becomes relevant, which
refers to the following questioning: what evidence is available in
the literature that addresses the participation of children and
adolescents, as asymptomatic carriers, in the control and
prevention of COVID-19 transmission?
This protocol describes the method of a systematic review that
will aim to identify the evidence available in the literature on the
participation of the child population in the control and
prevention of COVID-19 transmission, and also describe the
epidemiological profile and clinical and immunological charac-
teristics of COVID-19 in this population. A secondary aim of the
review will be to map the gradient of contribution of this
population in the dynamics of disease transmission.
2. Methods and analysis
2.1. Protocol and registration
This systematic review was recorded in the International
prospective register of Systematic reviews (PROSPERO) on




This protocol will be developed in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P),[8,9] and systematic review according to
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA),[10] which provides a selection flow diagram
(Fig. 1).
2.3. Search strategy
The searches will be conducted in 5 electronic databases
(PubMed, Web of Science, ScienceDirect, EMBASE, and Scopus)
by 2 independent researchers (ACFN andVHOS), whowill apply
the search strategies using the following terms: children, Child,
Adolescent, Student, Young children, Young people, Pupils,
School age; COVID-19, SARS-CoV-2 infection, Coronavirus
disease-19; transmission; Prevention and control, with boolean
operators AND and OR used between the terms. The Rayyan
QCRI[11] application (specific for systematic reviews) will be used
to read titles and abstracts, remove duplicates, and read full texts.
And for the management of references will be used the Software
Mendeley.[12] Initially, the reading by title and abstract will be
performed, after the removal of duplicates, and then, the
complete reading of the selected articles. If any abstract is not
provided using the search strategy, the full text of the manuscript
will be reviewed and evaluated. If the 2 independent researchers
disagree about the inclusion of any study in the review, a third
researcher (GP) will decide whether or not to include the study.
2.4. Eligibility Criteria
2.4.1. Types of studies. Clinical trials, observational studies,
and case reports describing the epidemiological profiles and
clinical-immunological characteristics of COVID-19 in children
and adolescents confirmed with SARS-CoV-2 infection, accord-
ing to WHO guidelines; and the participation of the child
population in the transmission dynamics of COVID-19.
2.4.2. Population. Children and adolescents (19 years)[13]
infected with SARS-CoV-2 were confirmed by the RT-PCR or
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serology method to identify previous infection and WHO
diagnostic criteria.
2.4.3. Intervention. For the intervention effect, SARS-CoV-2
infection will be considered, as well as the control and prevention
of COVID-19 transmission in children and adolescents.
2.4.4. Comparison. Several control interventions will be
included: level of severity of infection (severe/intensive care units
(ICU) versus nonsevere/non-ICU); existence of prespecified
comorbidities (diabetes mellitus, hypertension, chronic obstruc-
tive pulmonary disease, cardiovascular diseases, and others)
versus no comorbidities; children and adolescents with COVID-
19 who died will be compared with those who did not die; by
geographic region.
2.4.5. Exclusion criteria. Studies addressing children and
adolescents populations with psychological or intellectual
disabilities. Studies including only children and adolescents with
psychological or intellectual disabilities (mental retardation).
2.4.6. Types of outcomes. The main expected results include
data on the mean proportion or 95% confidence interval of:
incidence and mortality due to COVID-19 disease; early
comorbidities (diabetes, hypertension, and); complications (acute
respiratory distress syndrome, acute kidney injury, and so on);
the results of the course of the disease (hospitalization, discharge,
deaths, and so on); descriptions and data on the participation of
the child population in the transmission dynamics of COVID-19;
clinical and immunological characteristics of COVID-19 in the
infant population; demographic data (age, sex, race, country, and
so on) and clinical symptoms (fever, cough, and so on).
2.4.7. Data synthesis and analysis. The extraction of all data
will be done in a standardized manner by 2 independent authors
(KPMA and IDP), creating a database in a predesigned
spreadsheet and tested earlier in the Excel program. The
following information will be presented in this database:
identification of the studies (first author, author’s name, year
of publication, period of study, geographic region); participant’s
data (age, sample size, sex, period and duration of recruitment);
epidemiological information; clinical characteristics; data on the
participation of children and adolescents in the transmission
dynamics of COVID-19. For any relevant data lost, we will
contact the authors of the study. If we do not receive the necessary
information, or in the face of the impossibility of imputation of
the data, the results will be deleted from our analysis and will be
covered in the Discussion section in the discussion section, only
qualitatively.
Records after duplicates removed  
(n = ???) 
Records identified through database 
searching 



























Additional records identified 
through other sources  
(n = ???) 
WOS 
(n = ???) 
Records screened  
(n = ???) 
Records excluded with 
reasons (n = ???) 
Full-text articles assessed 
for eligibility  
(n = ???) 
ScienceDirect 
(n = ???) 
Full-text articles excluded, 
with reasons  
(n = ???) 
Studies included in the 
systematic review (n =???) 
Studies included in the 
meta-analysis (n = ???) 
EMBASE 
(n = ???) 
SCOPUS 
(n = ???) 
Figure 1. Flow diagram. Adapted from PRISMA-P.
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If there is a methodological homogeneity in the studies
included (at least 2) in the systematic review, a meta-analysis will
be performed. The evaluation of heterogeneity between the
studies will be performed by the statistical tests x2 and I2.
Random-effect or fixed-effect models will then be applied to
calculate the total size of the effect of the studies included in the
meta-analysis. If, however, the studies are considered too
heterogeneous, only a narrative synthesis will be performed.
The following criteria will be used: 0% to 40%, might not be
important; 30% to 60%, may represent moderate heterogeneity;
50% to 90%, may represent substantial heterogeneity; 75% to
100%, considerable heterogeneity.[14] For case studies included
with qualitative evidence, a metasynthesis approach will be
adopted.
2.5. Subgroup analysis
Subgroup analyses will be performed if relevant data are
available. If possible, the following will be performed: an
analysis of subgroups based on the children’s ages (newborns [0–
4 weeks]; infants [4 weeks–1 year]; children [12–24 months];
preschoolers [2–5 years; school-age children [6–12 years]; and
adolescents [13–19 years]); subgroup analysis based on location,
comorbidities mentioned previously, and laboratory character-
istics. In addition, the data will be analyzed according to the
drawings of the studies.
2.6. Bias risk assessment
The risk of bias assessment will be performed in a standardized
manner by 2 independent authors (KPMA and GCBSM), and
disagreements will be defined during consensus meetings. To
assess the risk of bias in the experimental studies included, the
Cochrane risk of bias tool (RoB 2.0)[15] will be applied, whereas
nonrandomized studies will be evaluated using a Risk of bias tool
to assess nonrandomized studies of interventions (ROBINS-I).[16]
If qualitative studies are included, the risk of bias will be
assessed using the Critical Appraisal Skills Program verification
checklist,[17] recommended by the Cochrane Collaboration for
qualitative literature.
2.7. Ethics and dissemination
Ethical approval and informed consent are not necessary for this
research, because it is a systematic review (use of secondary data).
3. Discussion
At the initial stage of the outbreak, COVID-19 was more
prevalent in people aged 15 years or older, and the proportion of
confirmed cases was relatively small in children. Since then, no
special prevention and control measures have been adopted in
this population, and the number of cases of childhood infection
has increased significantly, especially in younger age groups.[18]
Associated with this, children exhibit certain particularities and
cannot clearly describe their own health status or contact history,
which contributed to the serious challenge of protecting,
diagnosing, and treating this population.[19]
Although children and young adults are clearly susceptible to
SARS-CoV-2 infection, attention has focused primarily on their
potential role in influencing dissemination and transmission in
the community. Data reanalyzed from the epicenter of the
Chinese outbreak observed that children accounted for 12% of
infections.[20] However, understanding the protection mecha-
nism in children can help in the development of therapeutic goals
for the population considered primarily at risk, such as the
elderly. In addition, it is also important to identify the risks in
children to make recommendations on therapy and, where
available, vaccines.[21]
In the study conducted by DeBiasi et al (2020), from their
cohort of 177 pediatric patients, the authors highlighted the
potential for the worsening of the disease in this age group, and
sent an important warning to that other regions could adopt
measures of anticipation (prevention) and response (therapy)
against COVID-19, including a significant burden of children and
young adults hospitalized and in critical condition.[22]
We hope that the completed systematic review helps to
understand the main clinical features and management of
pediatric cases of SARS-CoV-2 infection and the dynamics of
transmission and control of the virus in this population.
Moreover, it may also help to define which strategies should
be used to control and prevention of COVID-19 transmission,
which is important to define pandemic and post-pandemic
recommendations for health care and self-care focusing this
population.
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